Signaling pathways that regulate basal ABC transporter activity at the blood- brain barrier

Current Pharmaceutical Design

Volumn 20, Issue 10, 2014, Pages 1463-1471

  Miller, David S ^a   Cannon, Ronald E ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

ABC transporters; Blood brain barrier; Drug delivery; Efflux pumps; Neuroprotection; P gp

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; ESTROGEN; FINGOLIMOD; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; PROTEIN KINASE C; SPHINGOLIPID; SPHINGOSINE 1 PHOSPHATE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD BRAIN BARRIER; BRAIN CANCER; BRAIN CAPILLARY; BRAIN PERFUSION; CENTRAL NERVOUS SYSTEM DISEASE; EPILEPSY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; HUMANS; SIGNAL TRANSDUCTION;

EID: 84897442309     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990457     Document Type: Review

References (56)

1. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis 2010; 37: 13-25.
2. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57: 178-201.
3. Winkler EA, Bell RD, Zlokovic BV. Central nervous system pericytes in health and disease. Nat Neurosci 2011; 14: 1398-405.
4. Daneman R, Zhou L, Kebede AA, Barres BA. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature 2010; 468: 562-6.
5. Quaegebeur A, Lange C, Carmeliet P. The neurovascular link in health and disease: molecular mechanisms and therapeutic implications. Neuron 2011; 71: 406-24.
6. Moitra K, Dean M. Evolution of ABC transporters by gene duplication and their role in human disease. Biol Chem 2011; 392: 29-37.
7. Hartz AM, Madole EK, Miller DS, Bauer B. Estrogen receptor beta signaling through phosphatase and tensin homolog/phosphoinositide 3-kinase/Akt/glycogen synthase kinase 3 downregulates blood-brain barrier breast cancer resistance protein. J Pharmacol Exp Ther 2010; 334: 467-76.
8. Ferry DR, Traunecker H, Kerr DJ. Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 1996; 32A: 1070-81.
9. Liang XJ, Aszalos A. Multidrug transporters as drug targets. Curr Drug Targets 2006; 7: 911-21.
10. Krishna R, St-Louis M, Mayer LD. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin. Int J Cancer 2000; 85: 131-41.
11. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 2011; 12: 723-38.
12. Agarwal S, Hartz AM, Elmquist WF, Bauer B. Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des 2011; 17: 2793-802.
13. Polli JW, Olson KL, Chism JP, et al. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethy l]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos 2009; 37: 439-42.
14. Agarwal S, Uchida Y, Mittapalli RK, Sane R, Terasaki T, Elmquist WF. Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice. Drug Metab Dispos 2012; 40: 1164-9.
15. Shawahna R, Uchida Y, Decleves X, et al. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol Pharm 2011; 8: 1332-41.
16. Bauer B, Hartz AM, Fricker G, Miller DS. Pregnane X receptor upregulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol 2004; 66: 413-9.
17. Bauer B, Yang X, Hartz AM, et al. In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol Pharmacol 2006; 70: 1212-9.
18. Wang X, Sykes DB, Miller DS. Constitutive androstane receptormediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. Mol Pharmacol 2010; 78: 376-83.
19. Wang X, Hawkins BT, Miller DS. Aryl hydrocarbon receptormediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. FASEB J 2011; 25: 644-52.
20. Chow EC, Durk MR, Cummins CL, Pang KS. 1Alpha, 25-dihydroxyvitamin D3 up-regulates P-glycoprotein via the vitamin D receptor and not farnesoid X receptor in both fxr(-/-) and fxr(+/+) mice and increased renal and brain efflux of digoxin in mice in vivo. J Pharmacol Exp Ther 2011; 337: 846-59.
21. Narang VS, Fraga C, Kumar N, et al. Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier. Am J Physiol Cell Physiol 2008; 295: C440-50.
22. Bendayan R, Lee G, Bendayan M. Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc Res Tech 2002; 57: 365-80.
23. Hawkins BT, Rigor RR, Miller DS. Rapid loss of blood-brain barrier P-glycoprotein activity through transporter internalization demonstrated using a novel in situ proteolysis protection assay. J Cereb Blood Flow Metab 2010; 30: 1593-7.
24. Kipp H, Pichetshote N, Arias IM. Transporters on demand: intrahepatic pools of canalicular ATP binding cassette transporters in rat liver. J Biol Chem 2001; 276: 7218-24.
25. Barakat S, Demeule M, Pilorget A, et al. Modulation of pglycoprotein function by caveolin-1 phosphorylation. J Neurochem 2007; 101: 1-8.
26. Barakat S, Turcotte S, Demeule M, et al. Regulation of brain endothelial cells migration and angiogenesis by P-glycoprotein/caveolin-1 interaction. Biochem Biophys Res Commun 2008; 372: 440-6.
27. Zhong Y, Hennig B, Toborek M. Intact lipid rafts regulate HIV-1 Tat protein-induced activation of the Rho signaling and upregulation of P-glycoprotein in brain endothelial cells. J Cereb Blood Flow Metab 2009.
28. Storch CH, Ehehalt R, Haefeli WE, Weiss J. Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J Pharmacol Exp Ther 2007; 323: 257-64.
29. McCaffrey G, Staatz WD, Sanchez-Covarrubias L, et al. Pglycoprotein trafficking at the blood-brain barrier altered by peripheral inflammatory hyperalgesia. J Neurochem 2012; 122: 962-75.
30. Ronaldson PT, Finch JD, Demarco KM, Quigley CE, Davis TP. Inflammatory pain signals an increase in functional expression of organic anion transporting polypeptide 1a4 at the blood-brain barrier. J Pharmacol Exp Ther 2011; 336: 827-39.
31. Lochhead JJ, McCaffrey G, Sanchez-Covarrubias L, et al. Tempol modulates changes in xenobiotic permeability and occludin oligomeric assemblies at the blood-brain barrier during inflammatory pain. Am J Physiol Heart Circ Physiol 2012; 302: H582-93.
32. Hartz AM, Madole EK, Miller DS, Bauer B. Estrogen receptor beta signaling through phosphatase and tensin homolog/phosphoinositide 3-kinase/Akt/glycogen synthase kinase 3 downregulates blood-brain barrier breast cancer resistance protein. J Pharmacol Exp Ther 2010; 334: 467-76.
33. Hartz AM, Mahringer A, Miller DS, Bauer B. 17-beta-Estradiol: a powerful modulator of blood-brain barrier BCRP activity. J Cereb Blood Flow Metab 2010; 30: 1742-55.
34. Mahringer A, Fricker G. BCRP at the Blood-Brain Barrier: Genomic Regulation by 17beta-Estradiol. Mol Pharm 2010.
35. Greenberg DA, Jin K. From angiogenesis to neuropathology. Nature 2005; 438: 954-9.
36. Hawkins BT, Sykes DB, Miller DS. Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor. J Neurosci 2010; 30: 1417-25.
37. Hawkins BT, Rigor RR, Miller DS. Rapid loss of blood-brain barrier P-glycoprotein activity through transporter internalization demonstrated using a novel in situ proteolysis protection assay. J Cereb Blood Flow Metab 2010; 30: 1593-7.
38. Miller DS. Xenobiotic export pumps, endothelin signaling, and tubular nephrotoxicants--a case of molecular hijacking. J Biochem Mol Toxicol 2002; 16: 121-7.
39. Hartz AM, Bauer B, Fricker G, Miller DS. Rapid regulation of Pglycoprotein at the blood-brain barrier by endothelin-1. Mol Pharmacol 2004; 66: 387-94.
40. Hartz AM, Bauer B, Fricker G, Miller DS. Rapid modulation of Pglycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and lipopolysaccharide. Mol Pharmacol 2006; 69: 462-70.
41. Cannon RE PJ, Hawkins BT, Campos CR, Miller DS. Targeting Blood-Brain Barrier Sphingolipid Signaling Reduces Basal PGlycoprotein Activity and Improves Drug Delivery to the Brain. Pric Nat Acad Sci 2012.
42. Bauer B, Hartz AM, Miller DS. Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol Pharmacol 2007; 71: 667-75.
43. Rigor RR, Hawkins BT, Miller DS. Activation of PKC isoform beta(I) at the blood-brain barrier rapidly decreases P-glycoprotein activity and enhances drug delivery to the brain. J Cereb Blood Flow Metab 2010; 30: 1373-83.
44. Strub GM, Maceyka M, Hait NC, Milstien S, Spiegel S. Extracellular and intracellular actions of sphingosine-1-phosphate. Adv Exp Med Biol 2010; 688: 141-55.
45. Choi JW, Gardell SE, Herr DR, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A 2011; 108: 751-6.
46. Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011; 69: 759-77.
47. Bauer B, Hartz AM, Pekcec A, Toellner K, Miller DS, Potschka H. Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol 2008; 73: 1444-53.
48. Edwards LJ, Constantinescu CS. Platelet activating factor/platelet activating factor receptor pathway as a potential therapeutic target in autoimmune diseases. Inflamm Allergy Drug Targets 2009; 8: 182-90.
49. Raggers RJ, Vogels I, van Meer G. Multidrug-resistance Pglycoprotein (MDR1) secretes platelet-activating factor. Biochem J 2001; 357: 859-65.
50. Ernest S, Bello-Reuss E. Secretion of platelet-activating factor is mediated by MDR1 P-glycoprotein in cultured human mesangial cells. J Am Soc Nephrol 1999; 10: 2306-13.
51. Rodrigues DH, Lacerda-Queiroz N, de Miranda AS, et al. Absence of PAF receptor alters cellular infiltrate but not rolling and adhesion of leukocytes in experimental autoimmune encephalomyelitis. Brain Res 2011; 1385: 298-306.
52. Callea L, Arese M, Orlandini A, Bargnani C, Priori A, Bussolino F. Platelet activating factor is elevated in cerebral spinal fluid and plasma of patients with relapsing-remitting multiple sclerosis. J Neuroimmunol 1999; 94: 212-21.
53. Kooij G, Backer R, Koning JJ, et al. P-glycoprotein acts as an immunomodulator during neuroinflammation. PLoS One 2009; 4: e8212.
54. Kooij G, van Horssen J, de Lange EC, et al. T lymphocytes impair P-glycoprotein function during neuroinflammation. J Autoimmun 2010; 34: 416-25.
55. Wang X, Hawkins BT, Miller DS. Activating PKC-beta1 at the blood-brain barrier reverses induction of P-glycoprotein activity by dioxin and restores drug delivery to the CNS. J Cereb Blood Flow Metab 2011; 31: 1371-5.
56. Campos CR, Schroter C, Wang X, Miller DS. ABC transporter function and regulation at the blood-spinal cord barrier. J Cereb Blood Flow Metab 2012; 32: 1559-66.